IFEZ to apply for designation of southern Ganghwa as free economic zone
The Incheon Free Economic Zone (IFEZ) Authority is set to submit its application by the end of June to designate the southern end of Ganghwa Island ...
Samsung Biologics drives foreign lead in Korea’s biotech supply chain
A surge in orders from Samsung Biologics Co., the world’s largest contract drugmaker, has propelled South Korea to the forefront of global rev...
South Korea’s Rznomics inks $1.3 bn out-licensing deal with Eli Lilly
Rznomics Inc., a South Korean RNA therapeutics developer, has signed an agreement worth more than $1.3 billion with US pharmaceutical giant Eli Lill...
ABL Bio lands $2.8 billion license-out deal with GSK
ABL Bio Inc., a South Korean biotech company, will license out its proprietary blood-brain barrier shuttle platform, called the Grabody-B, to UK-bas...
SillaJen: First to use lab-grown human tissue to find best cancer drug dose
South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical tria...
CHA Biotech seeks to resume healthcare unit IPO after affiliates’ merger
CHA Biotech Co., South Korea’s leading stem cell therapeutics developer, plans to resume an initial public offering of CHA Healthcare Co., a m...
LG, SNU team up to develop AI modeling for protein structure predictions
LG AI Research Institute, the artificial intelligence think-tank of LG Group, South Korea’s fourth-biggest conglomerate, on Thursday signed a ...
Partners Investment, GordonMD eye $150 mn biotech fund launch
South Korean venture capital firm Partners Investment said on Thursday it will raise up to 215.5 billion won ($150 million) in a biotech fund jointl...
Latvian President Rinkēvičs seeks closer ties with S.Korea in bio, defense
Latvian President Edgars Rinkēvičs, who is on a four-day working trip to South Korea, said on Friday he hopes for deeper cooperation between the two...
SK Bioscience sells stake in US vaccine developer Novavax
SK Bioscience Co., a drug-making arm of South Korea's No. 2 conglomerate SK Group, has sold a stake in Nasdaq-listed vaccine developer Novavax Inc. ...
Biotech stocks, foreigners’ top pick in Korea amid panic selling
Foreigners and institutional investors in the South Korean stock market picked biotechs as their favorite shares in hopes of a biopharma stock jump ...
Samsung to invest $52 mn in US biotech VC Flagship Pioneering
Samsung C&T Corp., its bio units Samsung Biologics Co. and Samsung Bioepis Co. and Samsung Venture Investment Corp. have committed a combined 72...
Samsung’s biotech duo on a roll with $1.1 bn CMO order
Samsung Group is on track to rise to the top of biosimilar companies in the world and become South Korea’s largest drug maker for contract man...
Dim outlook for Korean biotech firms’ rights offerings
South Korea’s bio and tech-heavy Kosdaq-listed Shaperon Inc. raised 12.7 billion won ($9.2 million) from its latest rights offering, selling o...
Korean biotech Bertis to join BIO 2024 for global reach
South Korean biotech Bertis Inc. will deliver presentations at the BIO International Convention, one of the world’s largest bio and healthcare...
Investors dump Korean biotech HLB stocks on FDA rejection
HLB Co. and its affiliate stocks tumbled on Friday on news that the South Korean biotech group’s highly anticipated new cancer treatment Rivoc...
Korean biotech Xcell Therapeutics eyes June IPO
South Korean biotech Xcell Therapeutics Inc., a developer of chemically defined media for in vitro cell culture, is aiming for a junior bourse Kosda...
Samsung Life Science invests in US biotech firm Latus Bio
Samsung Life Science Fund, managed by Samsung Group’s venture investment arm, has invested in US biotechnology firm Latus Bio Inc. during the ...
Samsung Biologics signs ADC CDO deal with LegoChem Bio
Samsung Biologics Co. has agreed with South Korean biotech company LegoChem Biosciences Inc. to provide contract development organization (CDO) serv...
Samsung’s Lee to spur M&As, new growth with ‘lost decade’ behind him
Cleared of wrongdoing charges that shackled his leadership for years, Samsung Group leader Jay Y. Lee now will actively seek mergers and acquisition...
Orion to buy control of biotech startup LegoChem for $415 mn
South Korea’s snack and confectionery maker Orion Group has agreed to buy a controlling stake in LegoChem Biosciences Inc., a Korean biotech s...
Samsung eyes biotech investments via Flagship Pioneering
Samsung C&T Corp., Samsung Biologics Co. and Samsung Bioepis Co. will ramp up investments in US biotechnology startups in collaboration with Fla...
LegoChem Bio, Janssen sign $1.7 bn ADC licensing deal
LegoChem Biosciences Inc. has signed a blockbuster $1.7 billion deal to license out its proprietary antibody drug conjugate (ADC) candidate to Jasse...
Peter Thiel-backed D&D Pharmatech gets preliminary nod for IPO
South Korean clinical-stage biotech D&D Pharmatech Inc. has won approval from the Korea Exchange’s preliminary review for listing on the j...
Samsung Biologics partners with Europe's largest VC
Samsung Biologics Co., the world's largest contract drug manufacturer, announced on Tuesday it has teamed up with global biotech venture capitalist ...
Proxy adviser ISS backs drug giant Celltrion's merger plan
South Korean drug giant Celltrion Group has received a positive recommendation from Institutional Shareholder Services (ISS), a global leading proxy...
NKMax's US subsidiary listed on Nasdaq
South Korean natural killer (NK) cell drugmaker NKMax Co. on Wednesday said its US subsidiary NKGen Biotech on Monday was listed on the Nasdaq Globa...
Wellmarker Bio signs worth of $528 mn tech transfer deal
Wellmarker Bio, South Korea's oncology drug development company, announced on Monday that it has signed a technology transfer agreement with a Europ...
AriBio applies for Phase 3 clinical trials in China for oral dementia drug
South Korean clinical-stage biotech company AriBio Co. on Thursday said it applied for Phase 3 clinical trials on the anti-Alzheimer's candidate t...
GI Innovation seeks to license allergy therapy to Japan in 2023
South Korea’s GI Innovation Inc. aims to complete licensing of its allergic diseases treatment candidate to a Japanese drug company by year's ...
